1. Home
  2. LPAA vs FDMT Comparison

LPAA vs FDMT Comparison

Compare LPAA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPAA
  • FDMT
  • Stock Information
  • Founded
  • LPAA 2024
  • FDMT 2013
  • Country
  • LPAA United States
  • FDMT United States
  • Employees
  • LPAA N/A
  • FDMT N/A
  • Industry
  • LPAA
  • FDMT Biotechnology: Pharmaceutical Preparations
  • Sector
  • LPAA
  • FDMT Health Care
  • Exchange
  • LPAA Nasdaq
  • FDMT Nasdaq
  • Market Cap
  • LPAA 299.3M
  • FDMT 391.8M
  • IPO Year
  • LPAA 2024
  • FDMT 2020
  • Fundamental
  • Price
  • LPAA $10.53
  • FDMT $10.75
  • Analyst Decision
  • LPAA
  • FDMT Strong Buy
  • Analyst Count
  • LPAA 0
  • FDMT 9
  • Target Price
  • LPAA N/A
  • FDMT $30.11
  • AVG Volume (30 Days)
  • LPAA 9.6K
  • FDMT 952.0K
  • Earning Date
  • LPAA 01-01-0001
  • FDMT 11-07-2025
  • Dividend Yield
  • LPAA N/A
  • FDMT N/A
  • EPS Growth
  • LPAA N/A
  • FDMT N/A
  • EPS
  • LPAA 0.35
  • FDMT N/A
  • Revenue
  • LPAA N/A
  • FDMT $33,000.00
  • Revenue This Year
  • LPAA N/A
  • FDMT $8,572.97
  • Revenue Next Year
  • LPAA N/A
  • FDMT $6.05
  • P/E Ratio
  • LPAA $29.90
  • FDMT N/A
  • Revenue Growth
  • LPAA N/A
  • FDMT N/A
  • 52 Week Low
  • LPAA $9.97
  • FDMT $2.24
  • 52 Week High
  • LPAA $10.70
  • FDMT $12.34
  • Technical
  • Relative Strength Index (RSI)
  • LPAA 59.01
  • FDMT 55.60
  • Support Level
  • LPAA $10.44
  • FDMT $10.60
  • Resistance Level
  • LPAA $10.54
  • FDMT $12.00
  • Average True Range (ATR)
  • LPAA 0.01
  • FDMT 0.93
  • MACD
  • LPAA -0.00
  • FDMT -0.10
  • Stochastic Oscillator
  • LPAA 90.00
  • FDMT 41.54

About LPAA Launch One Acquisition Corp. Class A Ordinary shares

Launch One Acquisition Corp is a blank check company.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Share on Social Networks: